Terms: = Ovarian cancer AND FOXO1, Q12778, FOXO1A, 2308, ENSG00000150907, FKH1, FKHR AND Treatment
25 results:
1. Multifactor assessment of ovarian cancer reveals immunologically interpretable molecular subtypes with distinct prognoses.
Guo Y; Li S; Li C; Wang L; Ning W
Front Immunol; 2023; 14():1326018. PubMed ID: 38143770
[TBL] [Abstract] [Full Text] [Related]
2. RUNX1 knockdown induced apoptosis and impaired EMT in high-grade serous ovarian cancer cells.
Chen Y; He Z; Yang S; Chen C; Xiong W; He Y; Liu S
J Transl Med; 2023 Dec; 21(1):886. PubMed ID: 38057816
[TBL] [Abstract] [Full Text] [Related]
3. HB-EGF induces mitochondrial dysfunction via estrogen hypersecretion in granulosa cells dependent on cAMP-PKA-JNK/ERK-Ca
Huang JC; Duan CC; Jin S; Sheng CB; Wang YS; Yue ZP; Guo B
Int J Biol Sci; 2022; 18(5):2047-2059. PubMed ID: 35342363
[TBL] [Abstract] [Full Text] [Related]
4. Inhibition of c-Myc using 10058-F4 induces anti-tumor effects in ovarian cancer cells via regulation of FOXO target genes.
Ghaffarnia R; Nasrollahzadeh A; Bashash D; Nasrollahzadeh N; Mousavi SA; Ghaffari SH
Eur J Pharmacol; 2021 Oct; 908():174345. PubMed ID: 34270986
[TBL] [Abstract] [Full Text] [Related]
5. Role of FOXO protein's abnormal activation through PI3K/AKT pathway in platinum resistance of ovarian cancer.
Shi YY; Meng XT; Xu YN; Tian XJ
J Obstet Gynaecol Res; 2021 Jun; 47(6):1946-1957. PubMed ID: 33827148
[TBL] [Abstract] [Full Text] [Related]
6. foxo1 mitigates the SMAD3/FOXL2
Secchi C; Benaglio P; Mulas F; Belli M; Stupack D; Shimasaki S
J Transl Med; 2021 Feb; 19(1):90. PubMed ID: 33639972
[TBL] [Abstract] [Full Text] [Related]
7. Integrated analysis of gene expression and DNA methylation profiles in ovarian cancer.
Gong G; Lin T; Yuan Y
J Ovarian Res; 2020 Mar; 13(1):30. PubMed ID: 32192517
[TBL] [Abstract] [Full Text] [Related]
8. Propofol inhibits proliferation and cisplatin resistance in ovarian cancer cells through regulating the microRNA‑374a/forkhead box O1 signaling axis.
Sun Y; Peng YB; Ye LL; Ma LX; Zou MY; Cheng ZG
Mol Med Rep; 2020 Mar; 21(3):1471-1480. PubMed ID: 32016462
[TBL] [Abstract] [Full Text] [Related]
9. Myometrial progesterone hyper-responsiveness associated with increased risk of human uterine fibroids.
Omar M; Laknaur A; Al-Hendy A; Yang Q
BMC Womens Health; 2019 Jul; 19(1):92. PubMed ID: 31288815
[TBL] [Abstract] [Full Text] [Related]
10. Integrated microarray meta-analysis identifies miRNA-27a as an oncogene in ovarian cancer by inhibiting foxo1.
Wang Z; Ji G; Wu Q; Feng S; Zhao Y; Cao Z; Tao C
Life Sci; 2018 Oct; 210():263-270. PubMed ID: 30138596
[TBL] [Abstract] [Full Text] [Related]
11. Goserelin promotes the apoptosis of epithelial ovarian cancer cells by upregulating forkhead box O1 through the PI3K/AKT signaling pathway.
Zhang N; Qiu J; Zheng T; Zhang X; Hua K; Zhang Y
Oncol Rep; 2018 Mar; 39(3):1034-1042. PubMed ID: 29286125
[TBL] [Abstract] [Full Text] [Related]
12. FoxO-1 contributes to the efficacy of the combination of the XPO1 inhibitor selinexor and cisplatin in ovarian carcinoma preclinical models.
Corno C; Stucchi S; De Cesare M; Carenini N; Stamatakos S; Ciusani E; Minoli L; Scanziani E; Argueta C; Landesman Y; Zaffaroni N; Gatti L; Perego P
Biochem Pharmacol; 2018 Jan; 147():93-103. PubMed ID: 29155058
[TBL] [Abstract] [Full Text] [Related]
13. Kinase-driven metabolic signalling as a predictor of response to carboplatin-paclitaxel adjuvant treatment in advanced ovarian cancers.
Sereni MI; Baldelli E; Gambara G; Ravaggi A; Hodge KA; Alberts DS; Guillen-Rodriguez JM; Dong T; Memo M; Odicino F; Angioli R; Liotta LA; Pecorelli SL; Petricoin EF; Pierobon M
Br J Cancer; 2017 Aug; 117(4):494-502. PubMed ID: 28664915
[TBL] [Abstract] [Full Text] [Related]
14. Downregulation of foxo1 mRNA levels predicts treatment failure in patients with endometrial pathology conservatively managed with progestin-containing intrauterine devices.
Reyes HD; Carlson MJ; Devor EJ; Zhang Y; Thiel KW; Samuelson MI; McDonald M; Yang S; Stephan JM; Savage EC; Dai D; Goodheart MJ; Leslie KK
Gynecol Oncol; 2016 Jan; 140(1):152-60. PubMed ID: 26524723
[TBL] [Abstract] [Full Text] [Related]
15. Novel reversible selective inhibitor of CRM1 for targeted therapy in ovarian cancer.
Liu X; Chong Y; Liu H; Han Y; Niu M
J Ovarian Res; 2015 Jun; 8():35. PubMed ID: 26055813
[TBL] [Abstract] [Full Text] [Related]
16. Induction of microRNA-9 mediates cytotoxicity of curcumin against SKOV3 ovarian cancer cells.
Zhao SF; Zhang X; Zhang XJ; Shi XQ; Yu ZJ; Kan QC
Asian Pac J Cancer Prev; 2014; 15(8):3363-8. PubMed ID: 24870723
[TBL] [Abstract] [Full Text] [Related]
17. Rapidly progressive congenital rhabdomyosarcoma presenting with multiple cutaneous lesions: an uncommon diagnosis and a therapeutic challenge.
Rekhi B; Qureshi SS; Narula G; Gujral S; Kurkure P
Pathol Res Pract; 2014 May; 210(5):328-33. PubMed ID: 24635971
[TBL] [Abstract] [Full Text] [Related]
18. Differential outcome of MEK1/2 inhibitor-platinum combinations in platinum-sensitive and -resistant ovarian carcinoma cells.
Cossa G; Lanzi C; Cassinelli G; Carenini N; Arrighetti N; Gatti L; Corna E; Zunino F; Zaffaroni N; Perego P
Cancer Lett; 2014 Jun; 347(2):212-24. PubMed ID: 24576622
[TBL] [Abstract] [Full Text] [Related]
19. BRCA1-IRIS overexpression promotes cisplatin resistance in ovarian cancer cells.
Chock KL; Allison JM; Shimizu Y; ElShamy WM
Cancer Res; 2010 Nov; 70(21):8782-91. PubMed ID: 20940403
[TBL] [Abstract] [Full Text] [Related]
20. Restoration of p53 functions protects cells from concanavalin A-induced apoptosis.
Amin AR; Thakur VS; Gupta K; Jackson MW; Harada H; Agarwal MK; Shin DM; Wald DN; Agarwal ML
Mol Cancer Ther; 2010 Feb; 9(2):471-9. PubMed ID: 20124456
[TBL] [Abstract] [Full Text] [Related]
[Next]
